Filing Details
- Accession Number:
- 0001209191-22-014653
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-02 16:01:19
- Reporting Period:
- 2022-02-28
- Accepted Time:
- 2022-03-02 16:01:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1446847 | Ironwood Pharmaceuticals Inc | IRWD | Pharmaceutical Preparations (2834) | 043404176 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1478448 | A Thomas Mccourt | C/O Ironwood Pharmaceuticals, Inc. 100 Summer Street, Suite 2300 Boston MA 02110 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Disposition | 2022-02-28 | 1,942 | $10.77 | 632,802 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2022-02-28 | 10,026 | $10.77 | 622,776 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2022-02-28 | 19,970 | $10.77 | 602,806 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2022-02-28 | 16,486 | $10.77 | 586,320 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on February 27, 2020.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 22, 2021.
Billionaire Hedge Funds
